2. Search Result
Search Result
Results for "

Lumisterol 3 (>90%)

" in MedChemExpress (MCE) Product Catalog:

614

Inhibitors & Agonists

7

Screening Libraries

3

Fluorescent Dye

24

Biochemical Assay Reagents

27

Peptides

9

Inhibitory Antibodies

61

Natural
Products

60

Recombinant Proteins

27

Antibodies

11

Click Chemistry

13

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112023
    Lumisterol 3 (>90%)

    9β,10α-Cholesta-5,7-dien-3β-ol; Cholecalciferol EP Impurity C

    		 Endogenous Metabolite Metabolic Disease
    Lumisterol 3 (>90%) (9β,10α-Cholesta-5,7-dien-3β-ol) is a normal human secosterooid metabolite from the class of vitamin D3 photoisomer derivatives. Lumisterol 3 (>90%) is used in the preparation of vitamin D .
    Lumisterol 3 (>90%)
  • HY-N0181A
    Lumisterol

    9β,10α-Ergosterol

    		 Endogenous Metabolite Metabolic Disease
    Lumisterol (9β,10α-Ergosterol), a steroid compound, is the (9β,10α)-stereoisomer of Ergosterol (HY-N0181). Lumisterol is a photoprotective agent against UVB-induced DNA damage and anti-proliferative activities .
    Lumisterol
  • HY-139348
    PFI-90

    		Histone Demethylase Apoptosis Cancer
    PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits PAX3-FOXO1 action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).
    PFI-90
  • HY-76383
    LR-90

    		Others Metabolic Disease Inflammation/Immunology
    LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes . LR-90 is also used in the research of diabetic animal model .
    LR-90
  • HY-162519
    LZFPN-90

    LZ90

    		 NAMPT PD-1/PD-L1 Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    LZFPN-90 (LZ90) is a dual NAMPT/PD-L1 targeting compound. LZFPN-90 inhibits PD-1/PD-L1 interaction and NAMPT activity. LZFPN-90 inhibits cell growth in a NAMPT-dependent manner and blocks the cell cycle, subsequently inducing apoptosis. LZFPN-90 exerted target-dependent antitumor activities, affecting metabolic processes and the immune system .
    LZFPN-90
  • HY-152027
    HSP90-IN-18

    		HSP Apoptosis Infection Neurological Disease Inflammation/Immunology Cancer
    HSP90-IN-18 is an effective heat shock protein 90 (Hsp90) inhibitor. HSP90-IN-18 has effective Hsp90 inhibitory activity with an IC50 value of 0.39 μM. HSP90-IN-18 can be used for the research of viral infection, neurodegenerative disease, and inflammation .
    HSP90-IN-18
  • HY-152028
    HSP90-IN-19

    		HSP Infection Neurological Disease Inflammation/Immunology Cancer
    HSP90-IN-19 is an effective heat shock protein 90 (Hsp90) inhibitor. HSP90-IN-19 has effective Hsp90 inhibitory activity with an IC50 value of 0.27 μM. HSP90-IN-19 can be used for the research of viral infection, neurodegenerative disease, and inflammation .
    HSP90-IN-19
  • HY-149891
    HSP90-IN-23

    		HSP Cancer
    HSP90-IN-23 (Comp 12-1) is an inhibitor of heat shock protein 90(HSP90) with an IC50 of 9 nM. HSP90-IN-23 induces apoptosis of tumor cells and arrests the tumor cell cycle in G0/G1 phase. HSP90-IN-23 can be used for cancer research .
    HSP90-IN-23
  • HY-170326
    HSP90-IN-35

    		Ligands for Target Protein for PROTAC HSP Cancer
    Hsp90-in-35 (Compound 379) is an inhibitor of Hsp90. The IC50 of HSP90-IN-35 for Her2 is between 0.05 and 0.5 μM. HSP90-IN-35 has antitumor activity. HSP90-IN-35 can be used to synthesize PROTAC (HY-153881) .
    HSP90-IN-35
  • HY-167827
    Hsp90-IN-34

    		HSP Cancer
    Hsp90-IN-34 (compound HAM-1) is a compound that inhibits the Aha1-Hsp90 chaperone complex with a high affinity for Hsp90/Aha1 (KDapp=23.5 µM). Hsp90-IN-34 modulates the ATPase activity of Hsp90 by affecting the interaction between Hsp90 and Aha1 .
    Hsp90-IN-34
  • HY-113574
    HSP90-IN-29

    		HSP Cancer
    HSP90-IN-29 (Compound 13), a benzoxazole derivative, is a potent and selective HSP-90 inhibitor with an IC50 value of 30 nM. HSP90-IN-29 has antitumor activity .
    HSP90-IN-29
  • HY-153051
    Antitumor agent-90

    		Others Cancer
    Antitumor agent-90 (Compound 17) has cytotoxicity against PC 14 cell and MKN 45 cell. Antitumor agent-90 can be used for cancer research .
    Antitumor agent-90
  • HY-144724
    HSP90-IN-10

    		HSP Apoptosis Cancer
    HSP90-IN-10 (Compound 16s) is a potent inhibitor of HSP90. HSP90-IN-10 exhibits high antiproliferative potency against HCC1954 breast cancer cells with the IC50 value of 6 µM. HSP90-IN-10 does not inhibit the growth of normal epithelial cells. HSP90-IN-10 also induces apoptosis .
    HSP90-IN-10
  • HY-146325
    HSP90-IN-11

    		HSP Cancer
    HSP90-IN-11 (Compound 12c) is a potent inhibitor of HSP90. HSP90-IN-11 displays potent HSP90α inhibition comparable to AUY-922 (Luminespib). HSP90-IN-11 shows significant antiproliferative activity in CRC and NSCLC cells in a double digit nM range. HSP90-IN-11 leads to rapid degradation of client proteins EGFR and Akt in NSCLC cells. HSP90-IN-11 induces significant accumulation of a sub-G1 phase population .
    HSP90-IN-11
  • HY-150655
    Hsp90-IN-15

    		HSP Cancer
    Hsp90-IN-15 is an Hsp90 inhibitor with anticancer activity. Hsp90-IN-15 induces cell apoptosis, arrests the cell cycle at S phase and decreases the expression level of Hsp90 in Hela cell .
    Hsp90-IN-15
  • HY-B1620H
    Polyvinylpyrrolidone K90

    PVP K90; Polyvidone K90; Povidone K90

    		 Biochemical Assay Reagents Infection
    Polyvinylpyrrolidone K90 can be used to prepare drug delivery systems, such as electrospun nanofibrous membranes. Polyvinylpyrrolidone K90 is widely used in human and veterinary medicine as an effective wound healing promoter and disinfectant when combined with iodine and other compounds. In addition, Polyvinylpyrrolidone K90 is also used to stabilize nanosuspensions, interact with the surface of drug crystals, and remain bound to the surface after drying [3].
    Polyvinylpyrrolidone K90
  • HY-B2144H
    Chitosan hydrochloride (80%-90% deacetylated)

    Chitosan HCl (80%-90% deacetylated)

    		 Bacterial Fungal Infection
    Chitosan hydrochloride 80%-90% deacetylated (Chitosan HCl 80%-90% deacetylated) is the deacetylated, hydrocholoride form of chitosan. Chitosan hydrochloride 80%-90% deacetylated is a polysaccharide obtained by deacetylating chitin, and exhibits antimicrobial activity against various bacteria and fungi. Chitosan hydrochloride 80%-90% deacetylated is utilized in agriculture, water treatment and pharmaceutical aspects .
    Chitosan hydrochloride (80%-90% deacetylated)
  • HY-149531
    HSP90-IN-25

    		HSP Cancer
    HSP90-IN-25 (compound 4a) is an HSP90 inhibitor that specifically inhibits the ATPase activity of HSP90 .
    HSP90-IN-25
  • HY-W089775
    Potassium phosphate tribasic monohydrate,90%

    		Biochemical Assay Reagents Others
    Potassium phosphate tribasic monohydrate,90% is a biochemical assay reagent.
    Potassium phosphate tribasic monohydrate,90%
  • HY-148963
    HSP90-IN-20

    		HSP Cancer
    HSP90-IN-20 (compound 78p) is a potent HSP90 inhibitor with an IC50 of ≤10 μM. HSP90-IN-20 has the potential for cancers research .
    HSP90-IN-20
  • HY-145814
    HSP90-IN-9

    		HSP Fungal Infection
    HSP90-IN-9 is a potent and selective HSP90 inhibitor. HSP90-IN-9 displays a fungicidal effect in a dose-dependent manner. HSP90-IN-9 inhibits fungal biofilm formation and fungal morphological changes after being combined with FLC. HSP90-IN-9 recovers FLC resistance by down-regulating the expression of related genes (ERG11, CDR1 and CDR2) .
    HSP90-IN-9
  • HY-168205
    HSP90-IN-33

    		HSP Apoptosis Cancer
    HSP90-IN-33 (compound 24e) is a potent Hsp90 inhibitor with Kd values of ≥200, 7.3 µM for Hsp90α, Hsp90β, respectively. HSP90-IN-33 induces apoptosis and cell cycle arrest at G0/G1 phase. HSP90-IN-33 decreases the protein expression of ERα, CDK4 and Akt .
    HSP90-IN-33
  • HY-156779
    HSP90-IN-27

    		HSP Cancer
    HSP90-IN-27 (compound 19) is an HSP90 inhibitor .
    HSP90-IN-27
  • HY-157389
    AK-HW-90

    		Bcr-Abl Cancer
    AK-HW-90 (compound 2B) is a potent panBcr-Abl inhibitor with significant inhibitory activity against Imatinib (HY-15463)-resistant mutants. AK-HW-90 inhibits the resistance mutant Bcr-Abl T315I with an IC50 of 0.65 nM. AK-HW-90 has potential anticancer activity and can be used in the study of chronic myelogenous leukemia (CML) .
    AK-HW-90
  • HY-161427
    HSP90-IN-30

    		HSP HIF/HIF Prolyl-Hydroxylase Cancer
    HSP90-IN-30 (compound 3e) inhibits HSP90 chaperone activity. HSP90-IN-30 inhibits the activity of HIF-1 transcriptional under hypoxia with an IC50 value of 2.16 μM .
    HSP90-IN-30
  • HY-163297
    Antifungal agent 90

    		Fungal Infection
    Antifungal agent 90 (Compound 7n) is an antifungal agent that inhibits ergosterol biosynthesis. Antifungal agent 90 showed excellent antifungal activity against Valsa mali and Botrytis cinerea with EC50 values respectively. 4.26 and 1.41 μg/mL .
    Antifungal agent 90
  • HY-131485
    3-Acetylpyridine adenine dinucleotide, 90%

    3-APAD, 90%; 3-Acetylpyridine NAD, 90%

    		 Lactate Dehydrogenase Metabolic Disease
    3-Acetylpyridine adenine dinucleotide, 90% is an analog of nicotinamide adenine dinucleotide (NAD). 33-Acetylpyridine adenine dinucleotide, 90% collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite .
    3-Acetylpyridine adenine dinucleotide, 90%
  • HY-146228
    HSP90-IN-13

    		HSP Apoptosis Topoisomerase EGFR VEGFR Cancer
    HSP90-IN-13 (compound 5k) is a highly potent HSP90 pan inhibitor with an IC50 value of 25.07 nM. HSP90-IN-13 has multi-target activity against EGFR, VEGFR-2 and Topoisomerase-2. HSP90-IN-13 causes cell cycle arrest at G2/M phase and induces apoptosis of MCF-7 cells through mitochondrial-mediated pathway .
    HSP90-IN-13
  • HY-151137
    HSP90/mTOR-IN-1

    		mTOR HSP Apoptosis Autophagy Cancer
    HSP90/mTOR-IN-1 is a potent and orally active Hsp90 and mTOR inhibitor with IC50 values of 69 nM and 29 nM, respectively. HSP90/mTOR-IN-1 suppresses the proliferation of SW780 cells through the over-activation of the PI3K/AKT/mTOR pathway. HSP90/mTOR-IN-1 induces apoptosis and autophagy via selective Hsp90 and mTOR inhibition. HSP90/mTOR-IN-1 also has considerable in vivo anti-tumor activity. HSP90/mTOR-IN-1 can be used for researching bladder cancer .
    HSP90/mTOR-IN-1
  • HY-151588
    Anticancer agent 90

    		Virus Protease Cancer
    Anticancer agent 90 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor activity. Anticancer agent 90 has high inhibition against the two cell line from ovarian cancer (OVCAR-4), renal cancer (A498) .
    Anticancer agent 90
  • HY-148215
    Hsp90-IN-17

    		HSP Cancer
    Hsp90-IN-17 (Example 5) is an HSP90 inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .
    Hsp90-IN-17
  • HY-148215A
    Hsp90-IN-17 hydrochloride

    		HSP Cancer
    Hsp90-IN-17 (Example 5) hydrochloride is an HSP90 inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .
    Hsp90-IN-17 hydrochloride
  • HY-151337
    Aha1/Hsp90-IN-1

    		Microtubule/Tubulin Neurological Disease Inflammation/Immunology
    Aha1/Hsp90-IN-1 (Compound 17) is an Aha1/Hsp90 complex inhibitor. Aha1/Hsp90-IN-1 disrupts Aha1/Hsp90 interactions with an IC50 of 3.32 μM. Aha1/Hsp90-IN-1 inhibits tau aggregation .
    Aha1/Hsp90-IN-1
  • HY-15071
    YM90K

    		iGluR Neurological Disease
    YM90K is a potent and selective AMPA receptor antagonist with a Ki of 84 nM. YM90K is less potent in inhibiting kainate (Ki of 2.2 μM) and NMDA (Ki of 37 μM) receptors. YM90K has neuroprotective actions .
    YM90K
  • HY-147974
    HSP90-IN-14

    		HSP Influenza Virus Infection
    HSP90-IN-14 (compound 4) is a potent Hsp90 (heat shock protein 90) inhibitor, with a Kd of 0.26 μM. HSP90-IN-14 shows anti-influenza virus activity in MDCK cells, with EC50 values of 2.6, 3.9, and 17 μM for influenza A/H3N2, A/H1N1, and B, respectively .
    HSP90-IN-14
  • HY-156457
    EGFR-IN-90

    		EGFR Cancer
    EGFR-IN-90 (compound 34) is an orally active EGFR inhibitor. EGFR-IN-90 shows inhibitory activity against EGFRL858R/T790M/C797S with an IC50 of 5.1 nM and inhibits the proliferation of the H1975-TM cell line harboring EGFRL858R/T790M/C797S with an IC50 of 0.05 μM. EGFR-IN-90 and inhibits tumor growth in the H1975-TM xenograft tumor model .
    EGFR-IN-90
  • HY-162604
    SARS-CoV-2-IN-90

    		SARS-CoV Infection
    SARS-CoV-2-IN-90 (compound 3i) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-90 can be used in coronavirus infection related research .
    SARS-CoV-2-IN-90
  • HY-156586
    ASN90

    		OGA Tau Protein Neurological Disease
    ASN90 is a specific and orally active O-GlcNAcase (OGA) enzyme inhibitor with IC50 value of 10.2 nM. ASN90 can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies .
    ASN90
  • HY-162900
    HSP90-IN-32

    		HSP Cancer
    HSP90-IN-32 is a Hsp90 C-terminal inhibitor that displays anti-proliferative activities against SKMel173, SKMel103, SKMel19 and A375 cells with IC50 values of 1.01 μM, 0.782 μM, 0.607 μM and 1.413 μM , respectively. HSP90-IN-32 is promising for research of anti-cancer agents .
    HSP90-IN-32
  • HY-161833
    HSP90-IN-31

    		Interleukin Related TNF Receptor Inflammation/Immunology
    HSP90-IN-31 (compound Be01) causes reduction of CD80 and CD86 expression on dendritic cells (DCs). HSP90-IN-31 decreases the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in BMDC and peritoneal macrophages stimulated by LPS (HY-D1056). Under the delayed-type hypersensitivity (DTH) mice model, HSP90-IN-31 reduces ear swelling and pro-inflammatory cytokines in the spleen .
    HSP90-IN-31
  • HY-12030
    PIK-90
    3 Publications Verification

    		 PI3K DNA-PK Cancer
    PIK-90 is a DNA-PK and PI3K inhibitor, which inhibits p110α, p110γ and DNA-PK with IC50s of 11, 18 and 13 nM, respectively.
    PIK-90
  • HY-144694
    HDAC/HSP90-IN-3

    		HSP HDAC Fungal Infection
    HDAC/HSP90-IN-3 (compound J5) is a potent and selective fungal Hsp90 and HDAC dual inhibitor, with IC50 values of 0.83 and 0.91 μM, respectively. HDAC/HSP90-IN-3 shows antifungal activity against azole resistant C. albicans. HDAC/HSP90-IN-3 can suppress important virulence factors and down-regulate drug-resistant genes ERG11 and CDR1 .
    HDAC/HSP90-IN-3
  • HY-W040233B
    Sodium (S)-2-hydroxypropanoate (purity≥90%)
    5 Publications Verification

    Sodium L-lactate (purity≥90%)

    		 Others Others
    Sodium (S)-2-hydroxypropanoate (Sodium L-lactate) (purity≥90%) is a buildiing block which can be used as a precursor for the production of the bioplastic polymer poly-lactic acid .
    Sodium (S)-2-hydroxypropanoate (purity≥90%)
  • HY-144650
    Hsp90-Cdc37-IN-3

    		Apoptosis HSP Cancer
    Hsp90-Cdc37-IN-3 (Compound 9) is a novel celastrol−imidazole derivative with anticancer activity. Hsp90-Cdc37-IN-3 inhibits Hsp90−Cdc37 by covalent-binding, and induces apoptosis .
    Hsp90-Cdc37-IN-3
  • HY-165911
    C90-Dolichol

    Dolichol-18

    		 Biochemical Assay Reagents Metabolic Disease
    C90-Dolichol (Dolichol-18) is an ester product.
    C90-Dolichol
  • HY-162173
    WYZ90

    		COX Inflammation/Immunology
    WYZ90 ((compound 6a) is a potent and selective COX-2 inhibitor with IC50 values of 75, 5734, 19940 nM for COX-2, COX-1 and DPPH, respectively. WYZ90 shows antioxidant and analgesic activity .
    WYZ90
  • HY-146212
    HDAC/HSP90-IN-4

    		HDAC HSP Cancer
    These compounds have strong hdac and hsp90 inhibitory activities. Compound 20 (HDAC ic50   =   194   nm; Hsp90 α < b> Ic50 =   153   nm) and compound 26 ((HDAC ic50=   360   nm; Hsp90 α < b> Ic50   =   77   nm) shows the strongest HDAC and HSP90 α Inhibitory activity. Both compounds can induce hsp90 expression and down regulate hsp90 client proteins, which play an important role in regulating the survival and invasion of cancer cells.
    HDAC/HSP90-IN-4
  • HY-W011696
    Oleylamine, 80-90%

    cis-1-Amino-9-octadecene, 80-90%

    		 Biochemical Assay Reagents Others
    Oleylamine, 80-90% (cis-1-Amino-9-octadecene, 80-90%) is a long-chain primary alkylamine, which can be used in nanoparticle synthesis as a solvent, surfactant, and reducing agent. Oleylamine, 80-90% forms metastable complexes with metal ions, which can be controllably decomposed to produce nanoparticles. Oleylamine, 80-90% can control the morphology of nanoparticle, prevent the nanoparticle aggregation, and reduce metal precursors to metal nanoparticles .
    Oleylamine, 80-90%
  • HY-155577
    MAO A/HSP90-IN-1

    		Monoamine Oxidase HSP Cancer
    MAO A/HSP90-IN-1 (4-b) is a MAO A/HSP90 dual inhibitor with IC50 value of 1.77 μM and 0.019 μM in Glioblastoma (GBM) GL26 cells and HSP90α, respectively. MAO A/HSP90-IN-1 (4-b) can inhibit MAO A activity, HSP90 binding and the expression of HER2 and phospho-Akt to inhibit the growth of GBM, they also reduce PD-L1 expression, which inhibits T cell activation. MAO A/HSP90-IN-1 (4-b) have potential to inhibit tumor immune escape. MAO A/HSP90-IN-1 (4-b) can be used for brain tumor-related diseases research .
    MAO A/HSP90-IN-1
  • HY-111414
    Hsp90-Cdc37-IN-1

    		HSP Cancer
    Hsp90-Cdc37-IN-1 is an Hsp90-Cdc37 interaction disruptor that inhibit cell migration and reverse agent resistance, with an IC50 of 140 nM.
    Hsp90-Cdc37-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: